Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.05
AKR's Cash-to-Debt is ranked lower than
53% of the 655 Companies
in the Global REIT - Retail industry.

( Industry Median: 0.06 vs. AKR: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
AKR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.17 Max: N/A
Current: 0.05
Equity-to-Asset 0.40
AKR's Equity-to-Asset is ranked lower than
74% of the 684 Companies
in the Global REIT - Retail industry.

( Industry Median: 0.51 vs. AKR: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
AKR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.29 Max: 0.4
Current: 0.4
0.18
0.4
Interest Coverage 0.63
AKR's Interest Coverage is ranked lower than
96% of the 664 Companies
in the Global REIT - Retail industry.

( Industry Median: 3.72 vs. AKR: 0.63 )
Ranked among companies with meaningful Interest Coverage only.
AKR' s Interest Coverage Range Over the Past 10 Years
Min: 0.63  Med: 1.17 Max: 1.38
Current: 0.63
0.63
1.38
Piotroski F-Score: 4
Altman Z-Score: 0.71
Beneish M-Score: -2.52
WACC vs ROIC
4.31%
0.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 11.52
AKR's Operating Margin % is ranked lower than
86% of the 692 Companies
in the Global REIT - Retail industry.

( Industry Median: 49.17 vs. AKR: 11.52 )
Ranked among companies with meaningful Operating Margin % only.
AKR' s Operating Margin % Range Over the Past 10 Years
Min: 11.52  Med: 26.83 Max: 33.72
Current: 11.52
11.52
33.72
Net Margin % 38.32
AKR's Net Margin % is ranked lower than
51% of the 693 Companies
in the Global REIT - Retail industry.

( Industry Median: 39.81 vs. AKR: 38.32 )
Ranked among companies with meaningful Net Margin % only.
AKR' s Net Margin % Range Over the Past 10 Years
Min: 18.17  Med: 30.42 Max: 52.68
Current: 38.32
18.17
52.68
ROE % 5.48
AKR's ROE % is ranked lower than
58% of the 696 Companies
in the Global REIT - Retail industry.

( Industry Median: 6.34 vs. AKR: 5.48 )
Ranked among companies with meaningful ROE % only.
AKR' s ROE % Range Over the Past 10 Years
Min: 5.41  Med: 8.81 Max: 14.68
Current: 5.48
5.41
14.68
ROA % 2.14
AKR's ROA % is ranked lower than
67% of the 700 Companies
in the Global REIT - Retail industry.

( Industry Median: 3.31 vs. AKR: 2.14 )
Ranked among companies with meaningful ROA % only.
AKR' s ROA % Range Over the Past 10 Years
Min: 1.92  Med: 2.26 Max: 3.24
Current: 2.14
1.92
3.24
ROC (Joel Greenblatt) % 4.36
AKR's ROC (Joel Greenblatt) % is ranked lower than
73% of the 585 Companies
in the Global REIT - Retail industry.

( Industry Median: 16.50 vs. AKR: 4.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AKR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.71  Med: 5.42 Max: 12.44
Current: 4.36
2.71
12.44
3-Year Revenue Growth Rate -6.60
AKR's 3-Year Revenue Growth Rate is ranked lower than
82% of the 500 Companies
in the Global REIT - Retail industry.

( Industry Median: 2.50 vs. AKR: -6.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AKR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -26.1  Med: 1.55 Max: 11.3
Current: -6.6
-26.1
11.3
3-Year EBITDA Growth Rate 1.30
AKR's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 457 Companies
in the Global REIT - Retail industry.

( Industry Median: 4.30 vs. AKR: 1.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AKR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.45 Max: 36
Current: 1.3
0
36
3-Year EPS without NRI Growth Rate 15.50
AKR's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 404 Companies
in the Global REIT - Retail industry.

( Industry Median: 5.40 vs. AKR: 15.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AKR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -10  Med: 13.5 Max: 38.7
Current: 15.5
-10
38.7
GuruFocus has detected 9 Warning Signs with Acadia Realty Trust $AKR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AKR's 10-Y Financials

Financials (Next Earnings Date: 2017-05-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AKR Guru Trades in Q1 2016

Chris Davis 733,787 sh (+17.11%)
Jim Simons 53,700 sh (+10.27%)
Ken Fisher 1,055,058 sh (-0.10%)
Pioneer Investments 99,300 sh (-3.22%)
» More
Q2 2016

AKR Guru Trades in Q2 2016

Paul Tudor Jones 12,667 sh (New)
Pioneer Investments 100,700 sh (+1.41%)
Jim Simons Sold Out
Ken Fisher 1,048,332 sh (-0.64%)
Chris Davis 484,458 sh (-33.98%)
» More
Q3 2016

AKR Guru Trades in Q3 2016

Ken Fisher 1,064,074 sh (+1.50%)
Chris Davis 484,457 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments 97,300 sh (-3.38%)
» More
Q4 2016

AKR Guru Trades in Q4 2016

Paul Tudor Jones 11,440 sh (New)
Chris Davis 497,226 sh (+2.64%)
Ken Fisher 1,033,784 sh (-2.85%)
Pioneer Investments 87,200 sh (-10.38%)
» More
» Details

Insider Trades

Latest Guru Trades with AKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: REITs » REIT - Retail    NAICS: 531120    SIC: 6798
Compare:NAS:ROIC, NYSE:NRF, NYSE:ALX, OTCPK:MEIYF, NYSE:SKT, NYSE:AAT, NYSE:KRG, NYSE:RPAI, NYSE:WPG, NYSE:CBL, OTCPK:CMPNF, NYSE:SRG, OTCPK:CWYUF, NYSE:BFS, NYSE:ADC, NYSE:TCO, OTCPK:SGLMF, NYSE:RPT, NYSE:PEI, OTCPK:PPRQF » details
Traded in other countries:WX1.Germany,
Headquarter Location:USA
Acadia Realty Trust is a real estate investment trust. It is engaged in the ownership, acquisition, redevelopment and management of retail properties located in supply-constrained, densely-populated metropolitan areas in the United States.

Acadia Realty Trust was formed on March 4, 1993 as a Maryland real estate investment trust. The Company is a fully-integrated equity real estate investment trust engaged in the ownership, acquisition, redevelopment, and management of retail properties located in supply-constrained, densely-populated metropolitan areas in the United States. The Company operates in three segments including Core Portfolio, Funds and Structured Financing. The Company's all assets are held by, and all of its operations are conducted through, Acadia Realty Limited Partnership and entities in which the Operating Partnership owns an interest. Its competitors include other REIT's, financial institutions, insurance companies, pension funds, private companies and individuals. Its properties compete for tenants with similar properties mainly on the basis of location, total occupancy costs and the design and condition of the improvements.

Top Ranked Articles about Acadia Realty Trust

Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)

THOROFARE, NJ--(Marketwired - Jun 27, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR) (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed its first distribution agreement for BreathScan OxiChek™ ("OxiChek") with Aero-Med, a division of Cardinal Health, a Fortune 500 health care services organization. Developed by Akers Bio as part of the Akers Wellness line, OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress in the body by measuring the levels of certain abundant free radicals. Frequent use of OxiChek may help health practitioners to monitor and adjust their clients' regimen of nutritional supplementation in order to manage oxidative stress -- an indicator of the overall health and wellbeing of a person. OxiChek works with BreathScan Lync™, the new Bluetooth-enabled reading device from Akers Wellness, to enable users to monitor oxidative stress via a mobile device.  Aero-Med is targeting the large specific markets in the United States of anti-aging, functional and integrative health and wellness treatment practitioners and has already placed orders for OxiChek. OxiChek will be initially represented by an Aero-Med sales team focusing on the six New England states both through direct sales and, in due course, through an e-commerce platform under development. Akers Bio intends to appoint further partners for OxiChek with distribution capabilities within other target markets for OxiChek including chiropractors and multi-level marketing organizations.  "The US health practitioner market is the most diverse in the world," said John J. Gormally, CEO of Akers Bio. "OxiChek targets many of these different potential user bases so we needed a distributor with the broadest reach and I can think of no organization better suited than Aero-Med, which has extensive access to our target markets. I have worked with Aero-Med in the past and have been highly impressed with their distribution capabilities," continued Mr. Gormally. Dan DelMastro, CEO of Aero-Med, added, "Aero-Med recognizes the enormous market potential for products within the health and wellness sector so we are delighted to be incorporating OxiChek into our sales offering. Having personally observed the positive customer reaction to OxiChek at conventions in recent months, I am optimistic that there is strong potential for this product." About Akers Biosciences, Inc. Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio. Cautionary Statement Regarding Forward Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3026507




For more information:



Akers Biosciences, Inc.

Raymond F. Akers, Jr., PhD

Co-founder and Chief Scientific Director

Tel. 1 856 848 8698



Taglich Brothers, Inc. (Investor Relations)

Chris Schreiber

Tel. 1 917 445 6207

Email: [email protected]



Vigo Communications (Public Relations)

Ben Simons / Fiona Henson

Tel. 44 (0)20 7830 9700

Email: [email protected]





Read more...
Akers Biosciences Reports Earnings for Q1 2016

PIFA Heparin/PF4 Rapid Tests Sales Up 88%; Total Revenues up 45%

THOROFARE, NJ--(Marketwired - May 12, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, reports its financial results for the first quarter ended March 31, 2016. Q1 Highlights

Product Revenue for Q1 was $738,023 (Q1 2015: $411,714) -- representing an increase of 79% over the corresponding quarter last year



Flagship PIFA Heparin/PF4 Rapid Assay products driving growth, with $635,173 worth of sales in Q1 (Q1 2015: $338,361) -- almost entirely to US hospitals -- representing an increase of 88% over the corresponding quarter last year



Demand for PIFA Heparin/PF4 Rapid Assay withstood the new increased pricing schedule implemented in Q1, reflecting clinical dependence on the test from existing customers



We believe that the new sales strategy of targeting hospital networks should now begin to accelerate growth in volumes as well as price



BreathScan Alcohol Breathalyzers sales ticking up with $64,785 generated in Q1 (Q1 2015: $41,361) -- with some sales coming from new markets including the UK and South Africa



Received $2,500,000 order for PIFA Heparin/PF4 Rapid Assay products from China during Q1 -- $250,000 already fulfilled in Q2 -- balance to ship at various intervals from now through December 31, 2016



Gross profit for Q1 was $537,995 (Q1 2015: $283,706) -- representing an increase of 90% over the corresponding quarter last year



Loss before income tax was $1,508,929 (Q1 2015: loss of $1,321,799) -- representing an increase of 14% arising mainly from non-recurring costs and costs associated with the re-organization of the sales and marketing staff and programs



Cash and marketable securities at March 31, 2016 was $2,622,857 (at December 31, 2015: $4,427,163) -- reflecting several significant non-recurring expenditures



An operational cost rationalization program was initiated in Q1 -- benefits expected to start flowing through late in Q2 and be fully realized in Q3 thereby accelerating path to profitability





Raymond F. Akers, Jr. PhD, Co-founder and Chief Scientific Director, commented: "During Q1, a new commercial team focused on driving sales of our flagship test for Heparin-induced thrombocytopenia (HIT) to US hospital Integrated Delivery Networks was put in place and a restructuring of our sales organization was initiated. An evidence based outcome proposition was implemented with our customers and distribution partners to improve our value expressed in price. The results are noteworthy. Domestic demand for this flagship test continues to grow, with $635,173 worth of sales recorded in Q1, coming almost entirely from US hospitals. This represents an increase of 88% over the corresponding quarter last year. It is encouraging to note that this sales growth is currently expressed mainly in the increase in the price of the products. This provides us with increasing confidence that, as the benefits of the sales strategy to focus on hospital networks begins to flow through, we are well placed to benefit from an accelerated increase in unit sales growth as well as price. The attractive growth in demand in the US for PIFA Heparin/PF4 Rapid Assay products is mirrored in China. In March, 2015 we announced a $2,500,000 order for PIFA Heparin/PF4 Rapid Assay products from our exclusive distributor for the tests in China, NovoTek Therapeutics Inc. A nominal amount from this order was fulfilled in Q1. $250,000 has already been fulfilled in Q2 and the substantial balance will be shipped at various intervals from now through December 31, 2016. The US and China business for PIFA Heparin/PF4 Rapid Assay is strongly underpinning the anticipated significant growth in revenues for this year, compared to last year. Another product showing signs of improvement in the current year is BreathScan Alcohol Breathalyzers. Whilst recording only a modest $64,785 in Q1 it should be noted that this includes initial sales to new customers in the UK and South Africa which may in time provide an increasing and recurring flow of revenues. We continue to advance the marketing and distribution strategy for new breath tests designed for the health and wellness industry via our Akers Wellness line. These include the consumer-focused METRON®, as well as the BreathScan OxiChek™ and BreathScan KetoChek™ tests which work with a new bluetooth-enabled reading device, BreathScan Lync™ and its associated Akers Wellness™ mobile app, to enable consumers and professional users to monitor trends in health via a mobile device. We believe that having the ability to generate near-instant health information is key to the future of medicine. With our Akers Wellness tests, clinicians, suppliers of nutritional supplements and diet plans, health coaches or even consumers themselves, can now monitor their -- or their clients' -- health over time by utilizing Akers Wellness products. We hope to see sales contributions from these tests towards the end of the current year as customer interest begins to translate into orders. The Company's gross margin improved significantly in Q1, rising to 73% as the benefits of price increases in our core product began to flow through, together with reduced costs associated with product manufacturing. This enabled the Company to achieve a gross profit of $537,995 -- a 90% increase on the corresponding quarter in 2015. Administrative, sales and marketing and R&D costs -- together with amortization of non-current assets -- turned this into a net loss of $1,516,958 for the quarter, an increase of 14%, arising mainly from non-recurring costs and the costs associated with the re-organization of the sales and marketing staff and programs. Outlook Early indicators of the Company's performance for 2016 are encouraging with US sales of PIFA Heparin/PF4 Rapid Assay products trending upwards, enhanced by a healthy order book for the shipment of these products into China. Furthermore, we believe our material reductions in overheads by the year end will accelerate our path to profitability. These factors alone -- regardless of any anticipated contribution from other products such as our breath based suite of tests -- underpin the Board's confidence that the Company will materially outperform 2015 in fiscal 2016." Summary of Statements of Operations for the Three Months Ended March 31, 2016 Revenue Akers Bio's revenue for the three months ended March 31, 2016 totalled $738,023, a 45% increase from the three months ended March 31, 2015. Product revenue increased by 79%, primarily a result of sales of our PIFA Heparin/PF4 Rapid Assay products. The elimination of license fee revenue following the cancellation of the License and Supply Agreement with ChubeWorkx Guernsey Limited in May, 2015 reduced the net revenue improvement year-over-year. The table below summarizes our revenue by product line for the three months ended March 31, 2016 and 2015 as well as the percentage of change year-over-year:


 
 
 
 
 
 
 
 
 
 


Product Lines
 
3 Months

Ended

March 31, 2016
 
 
3 Months

Ended

March 31, 2015
 
 
Percent

Change
 


MicroParticle Catalyzed Biosensor ("MPC")
 
$
64,785
 
 
$
41,361
 
 
 
57
%


Particle ImmunoFiltration Assay ("PIFA")
 
 
635,173
 
 
 
338,361
   
 
88
%


Other
 
 
38,065
 
 
 
31,992
 
 
 
19
%


Product Revenue Total
 
$
738,023
 
 
$
411,714
 
 
 
79
%


License Fees
 
 
-
 
 
 
98,333
 
 
 
(100
)%


Total Revenue
 
$
738,023
 
 
$
510,047
 
 
 
45
%


 
 
 
 
 
 
 
 
 
 
 
 
 



The Company's MPC product sales increased 57% during the three months ended March 31, 2016 over the same period of 2015. The increase is associated to sales of the Company's BreathScan Alcohol Breathalyzer products in Great Britain and increased domestic demand for the product which represents 53% of the Company's MPC product revenue. While all the MPC product sales in the three months ended March 31, 2016 came from BreathScan Alcohol Breathalyzers, we expect to begin generating sales of other MPC products within our health and wellness line, including the METRON disposable breath test for ketones and the BreathScan Lync products later in 2016. Domestic sales of the Company's PIFA Heparin/PF4 Rapid Assay products increased 80% during the three months ended March 31, 2016, primarily reflecting the new pricing schedule implemented during the period. Demand for the PIFA PF/4 Classic and PIFA PF/4 PLUSS products has remained steady, regardless of the increased pricing and we believe demand will increase with the implementation of the new sales and marketing strategy targeting hospital networks. The Company has restructured its sales and marketing staff, replacing the senior management team, reducing the number of Area Business Directors ("ABD") to five and implementing a highly targeted program to enhance the ABD's ability to expand market share through direct sales and by supporting the sales representatives of Akers' US distribution partners, Cardinal Health, Fisher HealthCare and Typenex Medical. The Company received a $2.5 million order for our PIFA Heparin/PF4 Rapid Assay products from Novotek, our exclusive distributor in the Peoples Republic of China on February 29, 2016. The Company received an initial payment of $250,000 on April 29, 2016 for the first scheduled product shipment, per the terms of sale. The remaining products will be scheduled to ship at various points throughout the current fiscal year with revenue being recognized when the criteria for the recognition of revenue is met. The Company also received a specialized order for PIFA Heparin/PF4 from Novotek, totaling $27,600 during the three months ended March 31, 2016. Other operating revenue increased due to a rise in miscellaneous component sales and shipping and handling fees. The Company's gross margin improved significantly, rising to 73% (2015: 56%) for the three months ended March 31, 2016. Cost of sales for the three months ended March 31, 2016 decreased by 12% to $200,028 (2015: $226,341). Direct cost of sales decreased to 11% of product revenue while other cost of sales decreased to 16% for the three months ended March 31, 2016 as compared to 12% and 43% respectively for the same period in 2015. General and Administrative Expenses General and administrative expenses for the three months ended March 31, 2016, totaled $923,560, which was a 32% increase as compared to $698,434 for the three months ended March 31, 2015. The increase in personnel costs for the three months ended March 31, 2016 is associated with the addition of a staff accountant in June 2015 and the Company's new Chief Executive Officer in November 2015. Professional service costs increased for the three months ended March 31, 2016. A significant increase in accounting and legal fees ($230,115 (2015: $75,775)) was offset by decreases in personnel recruiting and general consulting fees ($19,733 (2015: $90,942)). Increases in general consulting, stock exchange and transfer agent fees ($55,286 (2015: $34,065)) were offset by a significant decline in investor relations fees ($61,754 (2015: $95,454)) during the three months ended March 31, 2016 accounting for the decline in stock market and investor relations costs. Sales and Marketing Expenses Sales and marketing expenses for the three months ended March 31, 2016 totaled $725,324, which was a 26% increase as compared to $575,252 for the three months ended March 31, 2015. Research and Development Research and development expenses for the three months ended March 31, 2016 totaled $363,292, which was a 19% increase as compared to $305,574 for the three months ended March 31, 2015. Other Income and Expense Other income and expenses for the three months ended March 31, 2016 totaled $8,029, which was a 79% decrease as compared to $38,398 for the three months ended March 31, 2015. Liquidity and Capital Resources For the three months ended March 31, 2016 and 2015, the Company generated a net loss attributable to shareholders of $1,508,929 and $1,321,799, respectively. As of March 31, 2016 and December 31, 2015, the Company has an accumulated deficit of $95,684,928 and $94,175,999 and had cash and marketable securities totaling $2,622,857 and $4,427,163, respectively. Financial Statements A Form 10-Q containing the detailed report of operations and financial statements is available for viewing on the Company's website at www.akersbio.com or www.sec.gov. Conference Call Information: Thursday, May 12, 2016 at 9:00 a.m. Eastern Time
US: 1-888-359-3627

International: 1-719-457-1512

Conference ID: 2299421

Webcast: http://public.viavid.com/index.php?id=119627 About Akers Biosciences, Inc. Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio. Cautionary Statement Regarding Forward Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.


For more information, contact:



Akers Biosciences, Inc.

Raymond F. Akers, Jr. PhD

Co-founder and Chief Scientific Director

Tel. 1 856 848 8698



Taglich Brothers, Inc. (Investor Relations)

Chris Schreiber

Tel. 1 917 445 6207

Email: [email protected]



finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel. 44 (0)20 7220 0500



Vigo Communications (Public Relations)

Ben Simons / Fiona Henson

Tel. 44 (0)20 7830 9700

Email: [email protected]





Read more...
Akers Biosciences to Present at 'Pioneers 2016' Investor Conference

THOROFARE, NJ--(Marketwired - May 4, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company"), a developer of rapid health information technologies, is presenting at Joseph Gunnar & Co., LLC's 'Pioneers 2016' conference in New York on May 5, 2016. Co-founder and Chief Scientific Director, Raymond F. Akers, Jr. PhD, will give a presentation on the Company to institutional and accredited investors. About Akers Biosciences, Inc. Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio. Cautionary Statement Regarding Forward Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.


For more information:



Akers Biosciences, Inc.

Raymond F. Akers, Jr. PhD

Co-founder and Chief Scientific Director

Tel. 1 856 848 8698



Taglich Brothers, Inc. (Investor Relations)

Chris Schreiber

Tel. 1 917 445 6207

Email: [email protected]



Vigo Communications (Public Relations)

Ben Simons / Fiona Henson

Tel. 44 (0)20 7830 9700

Email: [email protected]





Read more...

Ratios

vs
industry
vs
history
PE Ratio 33.07
AKR's PE Ratio is ranked lower than
78% of the 613 Companies
in the Global REIT - Retail industry.

( Industry Median: 16.89 vs. AKR: 33.07 )
Ranked among companies with meaningful PE Ratio only.
AKR' s PE Ratio Range Over the Past 10 Years
Min: 9.21  Med: 27.68 Max: 48.82
Current: 33.07
9.21
48.82
Forward PE Ratio 68.49
AKR's Forward PE Ratio is ranked lower than
92% of the 342 Companies
in the Global REIT - Retail industry.

( Industry Median: 19.49 vs. AKR: 68.49 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.07
AKR's PE Ratio without NRI is ranked lower than
78% of the 612 Companies
in the Global REIT - Retail industry.

( Industry Median: 17.20 vs. AKR: 33.07 )
Ranked among companies with meaningful PE Ratio without NRI only.
AKR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.35  Med: 34.83 Max: 73.59
Current: 33.07
13.35
73.59
PB Ratio 1.60
AKR's PB Ratio is ranked lower than
74% of the 685 Companies
in the Global REIT - Retail industry.

( Industry Median: 1.12 vs. AKR: 1.60 )
Ranked among companies with meaningful PB Ratio only.
AKR' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 2.22 Max: 3.85
Current: 1.6
1.23
3.85
PS Ratio 12.32
AKR's PS Ratio is ranked lower than
81% of the 655 Companies
in the Global REIT - Retail industry.

( Industry Median: 7.50 vs. AKR: 12.32 )
Ranked among companies with meaningful PS Ratio only.
AKR' s PS Ratio Range Over the Past 10 Years
Min: 2.1  Med: 8.72 Max: 14.78
Current: 12.32
2.1
14.78
Price-to-Operating-Cash-Flow 21.06
AKR's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 567 Companies
in the Global REIT - Retail industry.

( Industry Median: 14.68 vs. AKR: 21.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.34  Med: 18.47 Max: 41.38
Current: 21.06
3.34
41.38
EV-to-EBIT 52.66
AKR's EV-to-EBIT is ranked lower than
89% of the 892 Companies
in the Global REIT - Retail industry.

( Industry Median: 21.84 vs. AKR: 52.66 )
Ranked among companies with meaningful EV-to-EBIT only.
AKR' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.7  Med: 36.4 Max: 158.2
Current: 52.66
13.7
158.2
EV-to-EBITDA 29.21
AKR's EV-to-EBITDA is ranked lower than
87% of the 904 Companies
in the Global REIT - Retail industry.

( Industry Median: 17.01 vs. AKR: 29.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.9  Med: 21 Max: 45.2
Current: 29.21
9.9
45.2
PEG Ratio 3.21
AKR's PEG Ratio is ranked lower than
62% of the 240 Companies
in the Global REIT - Retail industry.

( Industry Median: 2.17 vs. AKR: 3.21 )
Ranked among companies with meaningful PEG Ratio only.
AKR' s PEG Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.72 Max: 68.09
Current: 3.21
0.72
68.09
Shiller PE Ratio 32.50
AKR's Shiller PE Ratio is ranked lower than
60% of the 198 Companies
in the Global REIT - Retail industry.

( Industry Median: 24.18 vs. AKR: 32.50 )
Ranked among companies with meaningful Shiller PE Ratio only.
AKR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.03  Med: 29.61 Max: 74.11
Current: 32.5
12.03
74.11
Current Ratio 0.53
AKR's Current Ratio is ranked lower than
69% of the 651 Companies
in the Global REIT - Retail industry.

( Industry Median: 0.96 vs. AKR: 0.53 )
Ranked among companies with meaningful Current Ratio only.
AKR' s Current Ratio Range Over the Past 10 Years
Min: 0.53  Med: 4.16 Max: 9.81
Current: 0.53
0.53
9.81
Quick Ratio 0.53
AKR's Quick Ratio is ranked lower than
66% of the 651 Companies
in the Global REIT - Retail industry.

( Industry Median: 0.90 vs. AKR: 0.53 )
Ranked among companies with meaningful Quick Ratio only.
AKR' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 4.16 Max: 9.81
Current: 0.53
0.53
9.81
Days Sales Outstanding 84.25
AKR's Days Sales Outstanding is ranked lower than
89% of the 495 Companies
in the Global REIT - Retail industry.

( Industry Median: 17.68 vs. AKR: 84.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.08  Med: 74.6 Max: 385.52
Current: 84.25
50.08
385.52

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.25
AKR's Dividend Yield % is ranked lower than
88% of the 918 Companies
in the Global REIT - Retail industry.

( Industry Median: 5.21 vs. AKR: 3.25 )
Ranked among companies with meaningful Dividend Yield % only.
AKR' s Dividend Yield % Range Over the Past 10 Years
Min: 2.57  Med: 3.19 Max: 9.44
Current: 3.25
2.57
9.44
Dividend Payout Ratio 1.07
AKR's Dividend Payout Ratio is ranked higher than
55% of the 706 Companies
in the Global REIT - Retail industry.

( Industry Median: 1.06 vs. AKR: 1.07 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AKR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.24 Max: 1.68
Current: 1.07
0.79
1.68
3-Year Dividend Growth Rate 5.50
AKR's 3-Year Dividend Growth Rate is ranked higher than
60% of the 392 Companies
in the Global REIT - Retail industry.

( Industry Median: 4.20 vs. AKR: 5.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AKR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.1 Max: 10.8
Current: 5.5
0
10.8
Forward Dividend Yield % 3.31
AKR's Forward Dividend Yield % is ranked lower than
90% of the 920 Companies
in the Global REIT - Retail industry.

( Industry Median: 5.45 vs. AKR: 3.31 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.75
AKR's 5-Year Yield-on-Cost % is ranked lower than
70% of the 920 Companies
in the Global REIT - Retail industry.

( Industry Median: 6.04 vs. AKR: 4.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AKR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.76  Med: 4.67 Max: 13.81
Current: 4.75
3.76
13.81
3-Year Average Share Buyback Ratio -13.30
AKR's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 425 Companies
in the Global REIT - Retail industry.

( Industry Median: -5.70 vs. AKR: -13.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -48.8  Med: -7.75 Max: 0.9
Current: -13.3
-48.8
0.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.72
AKR's Price-to-Tangible-Book is ranked lower than
75% of the 677 Companies
in the Global REIT - Retail industry.

( Industry Median: 1.13 vs. AKR: 1.72 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AKR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.78  Med: 2.06 Max: 3.67
Current: 1.72
0.78
3.67
Price-to-Median-PS-Value 1.41
AKR's Price-to-Median-PS-Value is ranked lower than
83% of the 521 Companies
in the Global REIT - Retail industry.

( Industry Median: 1.08 vs. AKR: 1.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.54 Max: 1.47
Current: 1.41
0.1
1.47
Price-to-Peter-Lynch-Fair-Value 2.23
AKR's Price-to-Peter-Lynch-Fair-Value is ranked lower than
51% of the 124 Companies
in the Global REIT - Retail industry.

( Industry Median: 1.77 vs. AKR: 2.23 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AKR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.4  Med: 2.48 Max: 5.05
Current: 2.23
1.4
5.05
Price-to-Graham-Number 1.60
AKR's Price-to-Graham-Number is ranked lower than
76% of the 539 Companies
in the Global REIT - Retail industry.

( Industry Median: 0.95 vs. AKR: 1.60 )
Ranked among companies with meaningful Price-to-Graham-Number only.
AKR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.97  Med: 1.67 Max: 2.89
Current: 1.6
0.97
2.89
Earnings Yield (Greenblatt) % 1.90
AKR's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 914 Companies
in the Global REIT - Retail industry.

( Industry Median: 4.46 vs. AKR: 1.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 2.7 Max: 7.3
Current: 1.9
0.6
7.3
Forward Rate of Return (Yacktman) % -2.91
AKR's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 385 Companies
in the Global REIT - Retail industry.

( Industry Median: 2.48 vs. AKR: -2.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AKR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -27.7  Med: -1.3 Max: 20.9
Current: -2.91
-27.7
20.9

More Statistics

Revenue (TTM) (Mil) $189.9
EPS (TTM) $ 0.95
Beta0.54
Short Percentage of Float10.51%
52-Week Range $29.23 - 38.01
Shares Outstanding (Mil)83.63

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) 0.46 0.59
EPS without NRI ($) 0.46 0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 1.05 1.07
» More Articles for AKR

Headlines

Articles On GuruFocus.com
7 High-Yield Stocks With a Negative 1-Year Performance Feb 03 2017 
Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM) Jun 27 2016 
Akers Biosciences Reports Earnings for Q1 2016 May 12 2016 
Akers Biosciences to Present at 'Pioneers 2016' Investor Conference May 04 2016 
82 Shareholder Friendly Stocks of the Week Nov 10 2014 
Let's Take a Closer Look at Macerich Apr 09 2014 
My 5 Favorites Stocks With Dividend Growth From Last Week Mar 03 2013 
Urstadt Biddle Properties (UBA) Dividend Stock Analysis Nov 30 2012 
Acadia Realty Trust Reports Operating Results (10-K) Feb 28 2011 
Acadia Realty Trust (AKR) CFO Michael Nelsen sells 5,004 Shares Feb 22 2011 

More From Other Websites
REITs' Q1 Earnings to Watch on Apr 24: UDR, CCI & Others Apr 21 2017
Acadia Realty Trust breached its 50 day moving average in a Bullish Manner : AKR-US : April 14, 2017 Apr 14 2017
Acadia Realty Trust to Announce First Quarter 2017 Earnings on April 24, 2017 Mar 28 2017
Acadia Realty Trust Announces 2017 Annual Meeting Date Mar 24 2017
Acadia Realty Trust to Present at the Citi 2017 Global Property CEO Conference Mar 02 2017
Acadia Realty Trust Announces $0.26 Per Share Quarterly Dividend Mar 01 2017
New Strong Sell Stocks for March 1st Mar 01 2017
Acadia Realty Trust :AKR-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 Feb 17 2017
Edited Transcript of AKR earnings conference call or presentation 15-Feb-17 5:00pm GMT Feb 15 2017
Acadia Realty Trust : AKR-US: Dividend Analysis : December 30th, 2016 (record date) : By the numbers... Feb 15 2017
Acadia Realty Trust breached its 50 day moving average in a Bearish Manner : AKR-US : February 15,... Feb 15 2017
Acadia Realty Trust reports 4Q results Feb 14 2017
Acadia Realty Trust Reports Fourth Quarter and Full Year 2016 Operating Results Feb 14 2017
Acadia Realty Trust Completes $1.1 Billion of Transactions in 2016 Jan 18 2017
Acadia Realty Trust Announces Tax Reporting Information for 2016 Distributions Jan 13 2017
New Strong Sell Stocks for January 10th Jan 10 2017
Acadia Realty Trust to Announce Fourth Quarter 2016 Earnings on February 14, 2017 Jan 05 2017
Acadia Realty Trust breached its 50 day moving average in a Bullish Manner : AKR-US : January 5,... Jan 05 2017
ETFs with exposure to Acadia Realty Trust : January 3, 2017 Jan 03 2017
Is Acadia Realty Trust (AKR) A Good Stock To Buy? Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)